Studies suggest that GHRP-2 is a synthetic compound that may interact with a specific receptor, known as the ghrelin/growth hormone secretagogue receptor. Research trials have purported the possible impacts on muscle growth, immune system regulation, sleep cycles. Research on GHRP-2 has hinted at its bio-activity.
GHRP-2 Peptide: What is it?
GHRP-2, or Pralmorelin, is a manufactured growth hormone secretagogue that has been hypothesized to attach to the receptor responsible for ghrelin and growth hormone secretion. This peptide is believed to be the first of its kind in the field of growth hormone secretagogues. It is currently being researched for its potential in the context of growth hormone deficiency and secondary adrenal failure. GHRP-2 has been extensively studied in stage II clinical trials to evaluate its impact on various aspects such as appetite, muscle growth, the immune system, and sleep cycles. Ongoing research is focused on further understanding its potential in these areas.
GHRP-2 Peptide and Muscle Composition
Studies conducted on animals have suggested that GHRP-2 may have the potential to enhance muscle growth through two mechanisms: promoting protein deposition and reducing protein degradation.
The study purported that GHRP-2 might surpass the natural growth limitations experienced by animals due to factors such as food scarcity, illness, and challenging environmental circumstances like cold weather. The study further hunts at significant speculation- GHRP-2 may combat muscle atrophy by deactivating atrogin-1 and MuRF1, which are proteins responsible for regulating muscle degradation. These findings offer the potential for reducing the catabolism often seen in chronic illnesses such as autoimmune disease and cancer, among others.
By starting growth hormone and insulin-like growth factor-1, GHRP-2 has been theorized to enhance muscle protein deposition. Through minimizing degradation and promoting deposition, GHRP-2 is also assumed to stimulate the growth of lean body mass, even in challenging circumstances.
GHRP-2 Peptide and Hunger
GHRP-2 has been speculated to enhance food consumption. Although it may not be of immediate significance, appetite stimulation in research models of chronic diseases plays a crucial role in maintaining physiological equilibrium. The capacity to effortlessly and dependably enhance appetite may assist researchers in managing chronically ill research models and enhancing long-term outcomes.
GHRP-2 Peptide and the Heart
A study conducted on fetal heart cell culture lines has purported that GHRP-2 and its analogs, GHRP-1 and GHRP-6, may have the potential to safeguard heart cells by decreasing apoptosis, which is the process of programmed cell death. This is especially significant after a heart attack, as heart cells become more susceptible to apoptosis due to reduced blood flow and nutrient supply. Studies involving a synthetic compound similar to GHRP-2, known as Hexarelin, have suggested the existence of a potential receptor for these peptides.
Discovering novel receptors in various tissues not only paves the way for the development of innovative substances but may also enhance the comprehension of physiology and strategies to prevent dysfunction from occurring in the first place.
GHRP-2 Peptide and the Immune System
GHRP-2 has suggested the potential to activate the thymus, which is crucial in safeguarding specific immune cells. The thymus recreates a crucial role in the maturation of T cells. T cells play a vital function in adaptive immunity, enabling the organism to combat intricate infections effectively. The thymus's function decreases, resulting in various age-related issues. These include impaired tissue repair weakened immune system, making it harder to fight infections, protect against cancer, and maintain normal tissue function. GHRP-2 has been hypothesized to revitalize the thymus, potentially enhancing the quantity and variety of T cells it generates.
GHRP-2 Peptide and Sleep
Studies have implied that GHRP-2 may possibly enhance the span of sleep stages 3 and 4, each by approximately 50%. Additionally, it has been theorized to increase REM sleep by around 20% and reduce deviations from a typical sleep pattern by up to a third. Overall, the advancements in sleep appeared to have resulted in enhancements in cognitive function, blood pressure, tissue repair, and energy levels. Investigations purport that GHRP-2 could potentially provide valuable insights into optimizing sleep patterns to enhance quality.
GHRP-2 Peptide and Pain Perception
Initially, it was believed that the speculated reduction in pain in animal models of osteoarthritis was due to the potential of GHRP-2 on growth hormone levels, which in turn may have accelerated the healing process in the affected tissues. Observant scientists hinted that the pain relief appeared to have occurred before healing, suggesting that GHRP-2 might directly impact pain perception.
Four opioid receptors have been identified through scientific research. Many opioid pain compounds do not differentiate between them. This presents a challenge as certain receptors are involved in pain perception, while others play a role in regulating wakefulness, breathing, and even addiction. Studies suggest that GHRP-2 may selectively activate opioid receptors, primarily targeting the receptors associated with pain relief, sedation, and addiction. This discovery suggests the potential for developing targeted opioid agonists to minimize or even eliminate unwanted effects.
As a researcher, you can buy peptides in the USA if you are interested in further studying GHRP-2 peptides.
References
[i] R. Hu et al., “Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation,” PloS One, vol. 11, no. 2, p. e0149461, 2016. [PLOS ONE]
[ii] D. Yamamoto et al., “GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1,” Life Sci., vol. 82, no. 9–10, pp. 460–466, Feb. 2008. [PubMed]
[iii] L. T. Phung et al., “The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine,” Domest. Anim. Endocrinol., vol. 18, no. 3, pp. 279–291, Apr. 2000. [PubMed]
[iv] B. Laferrère, C. Abraham, C. D. Russell, and C. Y. Bowers, “Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men,” J. Clin. Endocrinol. Metab., vol. 90, no. 2, pp. 611–614, Feb. 2005. [PubMed]
[v] B. Laferrère, A. B. Hart, and C. Y. Bowers, “Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake,” Obes. Silver Spring Md, vol. 14, no. 6, pp. 1056–1063, Jun. 2006. [PMC]
[vi] G. Muccioli et al., “Growth hormone-releasing peptides and the cardiovascular system,” Ann. Endocrinol., vol. 61, no. 1, pp. 27–31, Feb. 2000. [PubMed]
[vii] V. Bodart et al., “Identification and characterization of a new growth hormone-releasing peptide receptor in the heart,” Circ. Res., vol. 85, no. 9, pp. 796–802, Oct. 1999. [AHA Journals]
[viii] D. D. Taub, W. J. Murphy, and D. L. Longo, “Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways,” Curr. Opin. Pharmacol., vol. 10, no. 4, pp. 408–424, Aug. 2010. [PubMed]
